Supreme Court To Take Drug Pricing Case

0 Shares

WASHINGTON (UPI) — The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.

 

 

 

The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.

 

 

 

The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.

 

 

 

“When drug companies agree not to compete, consumers lose,” FTC Chairman Jon Leibowitz said.

 

 

 

Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.

 

 

 

The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson’s agreement to hold a competitive drug off the market until 2015.

UPI - United Press International, Inc.

Since 1907, United Press International (UPI) has been a leading provider of critical information to media outlets, businesses, governments and researchers worldwide.

Join the Discussion

Comment Policy: We encourage an open discussion with a wide range of viewpoints, even extreme ones, but we will not tolerate racism, profanity or slanderous comments toward the author(s) or comment participants. Make your case passionately, but civilly. Please don't stoop to name calling. We use filters for spam protection. If your comment does not appear, it is likely because it violates the above policy or contains links or language typical of spam. We reserve the right to remove comments at our discretion.